Immunocore MAGE-A4 Investor & Analyst Event 2021

Virtual, December 6, 2021

Please join Immunocore for an upcoming Investor & Analyst event focused on the initial Phase 1 MAGE-A4 study.

The call will feature Dr. Diwakar Davar, University of Pittsburgh Medical Center.

Diwakar Davar, MBBS, M.Sc is an assistant professor of medicine and a medical oncologist/hematologist. He specializes in the management of advanced melanoma and the development of early phase studies to test novel immunotherapeutic approaches to treat advanced cancers. Dr. Davar is board-certified in internal medicine and medical oncology. He received his medical degree from National University of Singapore, and completed both his residency and fellowship at UPMC.


For more information or questions please reach out to William Windham (

RSVP Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Immunocore [IMCR] $1,205 MM MCap
Pi­oneer­ing the de­vel­op­ment of a nov­el class of T cell re­cep­tor (TCR) bis­pe­cif­ic im­munother­a­pies de­signed to treat a broad range of dis­eas­es, in­clud­ing can­cer, in­fec­tious and au­toim­mune dis­ease. MAGE-A4 Phase 1 Da­ta Q4 2021, tebenta­fusp PD­U­FA tar­get ac­tion date Feb. 2022, PRAME Phase 1 Da­ta Mid-2022. [more in­for­ma­tion]